Invitrogen contributes to new research into ALS

Invitrogen’s primary and stem cell systems business is participating in a new research programme designed to establish new treatment methods for amyotrophic lateral sclerosis (ALS).

The firm’s parent company Life Technologies has allied with the University of California, San Diego and the Salk Institute for Biological Studies to initiate studies into cell transplant therapy for the condition.

Expertise in the fields of stem cell biology, next-generation sequencing and bio-production is being provided by the Invitrogen business unit, in order help the research teams trial their pre-clinical concepts.

It is hoped that the research will create the foundation for future treatment of ALS and other neurodegenerative conditions.

Paul Pickering, general manager of the cell therapy systems segment of Life Technologies’ primary and stem cell systems unit, said: “Our scientists will bring together diverse technologies across multiple businesses at Life Technologies to provide a clinically compliant process intended to enhance the safety profile of this innovative therapeutic approach.”

Earlier this year, Invitrogen expanded its range of gene research technology with the launch of the new MAGic Sample Processor, which is designed to deliver fast and accurate results.